The Medical Technology Blog

Welcome back to the Medical Technology Blog, we have a great post today provided by our medical newsletters team-leader, Lawrence Miller. Lawrence is the editor for Medical Industry Week, please read on…

NTUH joins selective club that have achieved successful robotic-assisted kidney transplant.

An organ transplant team at National Taiwan University Hospital (NTUH) has become the first to carry out a robotic-assisted kidney transplant procedure in Asia.

The procedure involved the use of Intuitive Surgical’s da Vinci robotic surgery system, an FDA cleared system that is approved in the US for use in urological, general laparoscopic, gynaecologic laparoscopic, selected transoral otolaryngology, general thoracoscopic and thoracoscopically-assisted cardiotomy surgical procedures. Whilst robotic surgery has been used in all kinds of operations on human, robotic surgery has not gained widespread use in organ transplantation, due to insufficient manoeuvring space caused by the implant organ, as well as the requirement for a precise vascular suture technique and risk of haemorrhage. So far, only a few cases from European and American countries have been reported in literature.

The traditional open transplant requires a 15 to 20 cm incision, but causes more pain and discomfort for patients, and can trigger wound hernia due to high tension. In order to reduce postsurgery discomfort for patients, the NTUH organ transplant team has been working developing a robotic surgery system for organ transplantation.

In late July, NTUH’s organ transplant team successfully completed the milestone procedure. The surgery requires a few small incisions and efficiently decreases the possibility of complications. The team believes that accomplishment of this robotic assisted kidney transplant is an important milestone for organ transplant development.

The da Vinci system is used to used to mirror the movement of the surgeon’s hands using two controller sticks. The system offers high definition 3D vision and magnified views. Additionally, in comparison to traditional surgical techniques it is regarded as minimally invasive, offering the patients the benefits of rapid recovery and a small incision, whilst lowering the potential for complications.

Article Source: Medical Industry Week (MIW)

 




Espicom Business Intelligence
The Medical Technology Blog

Latest edition of The World Medical Markets Fact Book 2012!

Puts thousands of key medical market statistics and trends at your fingertips – now with analysis by medical technology sectors

In these challenging economic times the need to understand world medical markets and be able to answer quickly those questions that arise daily is essential.  That is why an authoritative, current and comprehensive market intelligence and statistics source is an invaluable aid for every industry executive.  And that source is the best-selling The World Medical Markets Fact Book 2012

Completely revised and updated for 2012, this highly-detailed and market-leading business reference draws from a vast range of primary national/international government and commercial sources to provide a comprehensive range of hard-to-find business information on the markets for medical devices worldwide.

THE NEW, IMPROVED AND EXPANDED 2012 FACT BOOK BRINGS THE WORLD TO YOU
  • Comprehensive coverage of 66 markets around the world
  • Five years (2006-2011) data and trend analysis by key medical technology sector (eg Diagnostic Imaging, Patient Aids)
  • Five years (2006-2011) data and trend analysis for key market indicators

- Demography (eg population, growth, life expectancy)
- Economic (eg health expenditure)
- Healthcare infrastructure and personnel (eg hospitals, beds, surgical procedures)

  • Rankings and overview for the world and 5 major regions
  • Individual country statistics
  • Over 500 detailed tables and charts
AN EXCELLENT NEW BENEFIT: ALL CUSTOMERS CAN ACCESS THE FACT FILE IN ESPICOM INTERACTIVE

The Fact Book is rich in tables and charts, and with Espicom Interactive online you can access and use this key data easily.  All tables can be instantly exported to MS Excel™ and Charts to MS PowerPoint™ while the fast search quickly pinpoints the data you need.  Best of all, Espicom Interactive is included in the report’s price!

THE FACT BOOK ANSWERS KEY BUSINESS QUESTIONS SUCH AS…
  • Which country spends most on medical devices as a % of GDP?
  • How are the economic downturn and currency fluctuations affecting key markets?
  • Which medical device sectors are growing the fastest?
  • How does the Brazilian market compare with China and India in terms of total health expenditure?
  • What demographic development is affecting the market in Central and Eastern Europe?
  • What have been the key trends affecting medical technology companies in leading emerging Latin American Markets?
ORDER YOUR COPY TODAY WITH ESPICOM INTERACTIVE INCLUDED IN THE PRICE!

For more information or to order a copy of this report please visit www.espicom.com/mfb


Mouse here for
Related Links



Espicom Business Intelligence

Business Monitor International aquires Espicom Business Intelligence

The Medical Technology Blog

Business Monitor International strengthens its pharmaceutical and medtech portfolio with acquisition of Espicom Business Intelligence

Business Monitor International, leading provider of country risk, financial markets and industry research across global markets, has announced the acquisition of Espicom Business Intelligence in a move which signals BMI’s continuing commitment to deepening its presence in key market sectors.

London, UK, August 21 2012 – Business Monitor International (“BMI”) has announced the acquisition of Espicom Business Intelligence (“Espicom”), a UK-based company with a 30-year pedigree providing business intelligence on Medical Devices, Pharmaceuticals & Healthcare and Therapeutics across global markets.  The acquisition reflects BMI’s commitment to deepening its market coverage of more than 20 industry verticals with specialist product and company intelligence. The financial terms of the transaction have not been disclosed.

The acquisition brings to BMI Espicom’s wide-range of information and business intelligence services for the global healthcare industries. In medical technology and devices, Espicom’s service features coverage of key operators in 70 country markets, proprietary 5-year forecasts, daily news on key technologies and critical management reports on areas such as advanced wound care, diagnostic products and market access. In pharmaceuticals, Espicom’s service features country-level data, therapeutics, generics and biosimilars markets coverage and specialized drug development database services.

BMI co-CEO Jonathan Feroze commented that “Espicom’s product and company level content, combined with BMI’s existing pharmaceuticals and healthcare coverage across 97 countries, will produce a holistic, market-leading offering”. Co-CEO Richard Londesborough added that “the acquisition of Espicom deepens our content portfolio in a highly strategic growth segment for BMI”.

Espicom founder and CEO Eric Wigart, added that “BMI is the ideal platform for bringing Espicom’s content to a wider audience.  Leveraging BMI’s global research, sales and account management capabilities will be a win-win for both companies”.

About Business Monitor International

Head-quartered in London, Business Monitor International (“BMI”) provides multinational corporations, financial institutions and government with integrated country risk, financial markets and industry research across 170 country markets and more than 20 industry verticals, with unrivalled coverage of emerging and frontier markets. Business Monitor Online, the company’s flagship online subscription service, features timely analysis, proprietary forecasts and risk ratings and rankings. Backed since 2009 by Spectrum Equity Investors, BMI has achieved rapid organic growth over the last decade, and now counts more than 400 of the Fortune Global 500 among its clients.

 

ENDS

 

Contacts

Matthew Brooks

Business Monitor International

·         mbrooks@businessmonitor.com

·         Tel: +44 (0)207 246 5117

Nigel Chivers

Espicom Business Intelligence

·         nigel_chivers@espicom.com

·         Tel: +44 (0)7793 211899




Espicom Business Intelligence

New report from Espicom: The Global Advanced Wound Care Market to 2017

The Medical Technology Blog

New report: The Global Advanced Wound Care Market to 2017

As the advanced wound care market tops US$5.5 billion, private finance and pharma are playing an increasingly influential role in its development.  What does it mean for the sector?

Mergers and acquisitions have always played a key role in the advanced wound care industry and have enabled the market leaders to expand their technology to address new sections of the market and provide access to new technologies.  But things are hotting up.  Smith & Nephew continues to add to its portfolio with the acquisition in May 2012 of Kalypto Medical while pharmaceutical companies flex their financial muscle: Shire purchased BioHealing in June 2011 while Sanofi purchased Genzyme in April 2011.

Private equity is getting more involved in the sector.  The headline acquisition of the NPWT leading company KCI by the APAX consortium is just the latest of a string of private equity transactions.  Nordic Capital and Avista Capital Partners purchased ConvaTec in August 2008, Systagenix was formed in December 2008 through One Equity Partners’ purchase of Ethicon Professional Wound Care, and Investor AB took full control of Mölnlycke in late 2010.

But what of the future?  With price pressures in the NPWT sector and low prices driven by high competition in the Moist Dressings sector, the spotlight has been thrown on Biologics.  While all sectors are expected to return to stronger annual growth, only the Biologics sector is expected to maintain double digit growth from 2015 onwards as products currently in development are launched.

THIS NEW (JULY 2012) MARKET RESEARCH REPORT PROVIDES A COMPLETE REVIEW AND ANALYSIS

  • Extensive competitive and product analysis of 109 major and emerging companies
  • Market share for leading companies
  • Growth forecasts and market share to 2017 by principal product area and geographical region

THE REPORT ANSWERS KEY BUSINESS QUESTIONS SUCH AS…

  • What next for Kinetic Concepts after its litigation troubles?
  • What % of the European market will moist dressings account for in 2017?
  • Who’s developing products in the skin substitution market?
  • Who’s partnering whom, and on what?
  • Which are the companies and technologies to watch?

ALL ADVANCED WOUND CARE SECTORS ARE COVERED INCLUDING:

Device-based advanced wound care

  • Negative Pressure Wound Therapy
  • Electrical Stimulation
  • Ultrasound
  • Extracorporeal Shock Wave Therapy

Moist wound care

  • Hydrogels
  • Hydrocolloid Dressings
  • Alginates
  • Foam Dressings
  • Composite Dressings
  • Activated Charcoal Dressings
  • Transparent Film Dressings
  • Antimicrobial Dressings
  • Silver Dressings

Biologics

  • Collagen-Based Wound Care Products
  • Skin Substitutes
  • Growth Factors
  • Cell-Based Therapies
  • Enzymatic Debriding Agents

 A NEW, REALLY USEFUL AND FREE BENEFIT: ESPICOM INTERACTIVE

This report is rich in tables and charts, and with Espicom Interactive online you can access and use this key data easily.  All tables can be instantly exported to MS Excel™ and Charts to MS PowerPoint™ while the fast search quickly pinpoints the data and information you need.  Support agents and overseas colleagues with instant translation into 9 languages. And best of all? Espicom Interactive is included in the report’s price!

ORDER YOUR COPY TODAY

You can buy your copy of The Global Advanced Wound Care Market to 2017 now.  For further information on the report’s extensive contents, please click here(www.espicom.com/awc).  Please note that prepayment is not required on this report.

Visit www.espicom.com to view all of our latest products.



Espicom Business Intelligence

Latest company to meet Roper’s key acquisition:Sunquest

The Medical Technology Blog

Sunquest becomes latest company to meet Roper’s key acquisition criteria

Welcome back to the Medical Technology Blog, we have a great post today provided by Sophie Sanderson. Sophie is the editor for Diagnostics Focus , please read on…

Adding to its vastly expanding medical platform and honing in on its focus on diagnostics, Roper Industries has set its sights on the acquisition of Sunquest Information Systems, a provider of diagnostic and laboratory information systems to healthcare providers worldwide, in an all cash transaction valued at nearly US$1.5 billion.

Roper expects the acquisition of Tucson, AZ-based Sunquest to be immediately cash enhancing and to generate around US$140 million or more of EBITDA in 2013. Sunquest, which has offices in the UK and India, is owned by a group of investors resulting from a 2010 recapitalisation led by Huntsman Gay Global Capital, in partnership with Vista Equity Partners, which has owned the company since 2007. Sunquest is expected to be an ideal fit with Roper’s Medical and Software platforms – which represents just one of the latters four business segments.

Roper is perhaps more commonly known as a designer, manufacturer and distributor of radiofrequency products and services, industrial technology products, energy systems and controls, as well as medical and scientific imaging products and software. Roper’s Medical and Scientific Imaging segment primarily offers products and software in medical applications, high performance digital imaging products and software, and hand-held and vehicle mount computers.

Focusing on the company’s Medical and Scientific Imaging segment, net sales in this area for 2011 were US$611 million, representing 22 per cent of Roper’s total net sales, which reached an impressive US$2.8 billion. Acquisitions alone added US$26 million in sales for the year ended 2011.

With claims that its balance sheet is stronger than ever before, and enjoying the more recurring revenue from its disciplined acquisitions of the last several years, it is unlikely that Sunquest will be the last in a string of revenue-generating acquisitions for the company.

Source material: Diagnostics Focus

 




Espicom Business Intelligence

MiCardia’s successful fundraising venture

The Medical Technology Blog

MiCardia gets busy with its mitral valve technology

Welcome back to the Medical Technology Blog. In the first instalment of her guest blog, Coral Campbell highlights interesting developments from Irvine, CA-based MiCardia. Please read on…

MiCardia has had its hands full this week with a successful fundraising venture that received the thumbs up from its investors and culminated with the spin-off of its transcatheter technology.

The spin-off company, called ValCare, has backing from an Israeli investor, will be hoping for big things from its transcatheter technology. The venture has US$8.0 million to further advance the technology and holds the intellectual property for the company’s transcatheter mitral valve repair system.

ValCare’s transcatheter mitral valve repair system uses interventional cardiology methods to implant a mitral annuloplasty device – a target market potential that has been touted to be worth upwards of US$3.5 billion. The next job for the company is to complete the development and test the device in pre-clinical studies in the near term.

Back at MiCardia, investors have given the company a vote of confidence by backing a near US$4.5 million funding programme. The cash will help support the business during the rest of 2012 and 2013. MiCardia plans to use the proceeds of this funding to expand the commercialisation of its enCorSQ mitral valve repair system in Europe and selected countries worldwide.

Article Source: Cardiovascular Device Business



Espicom Business Intelligence

FDA unveils plans for device ID system

The Medical Technology Blog

FDA unveils plans for device ID system for medical devices

 

Welcome back to the Medical Technology Blog, we have a great post today provided by our medical newsletters team-leader, Lawrence Miller. Lawrence is the editor for Medical Industry Week, please read on…

FDA proposal

In response to requirements in legislation that passed US Congress, the FDA has proposed that most medical devices distributed in the US carry a unique device identifier (UDI) in a move aimed at improving the quality of information in medical device adverse events reports.

The plans, which are now the subject of a 120 day comment period, aim to help the FDA identify product problems more quickly, better target recalls and improve patient safety. So far, the agency has conducted four pilot studies in the development of this proposed rule. With certain exceptions, under the proposed rule, a UDI would include a device identifier, which is a unique numeric or alphanumeric code specific to a device model; and a production identifier, which includes the current production information for a device.

Risk-based, phased-in

The FDA is proposing a “risk-based, phased-in” approach to implementation, focusing on the highest-risk medical devices first and exempting low-risk devices from some or all of the requirements. The agency is proposing to exempt OTC devices sold at the retail level as these devices generally have UPC codes in place.

A UDI acts as a key to certain basic identifying information about a device, such as the name of the manufacturer and the type of device, and may represent certain other information about the device, such as its expiration date and batch or lot number. This information will be contained in a publicly available UDI database called Global Unique Device Identification Database (GUDID), which will not contain any identifiable patient information.

The plans target the more accurate reporting, reviewing and analysing of adverse event reports so that problem devices can be identified and corrected more quickly. Other benefits include a reduction in medical errors and better management of medical device recalls.

Article Source: Medical Industry Week (MIW)




Espicom Business Intelligence

German researchers look at materials to keep stents secure

The Medical Technology Blog

German researchers look at materials to keep stents secure

Welcome back to the Medical Technology Blog, we have a great post today provided by our medical newsletters team-leader, Lawrence Miller, Lawrence is the editor for Cardiovascular Device Business, please read on…

Researchers from the Fraunhofer Institute in Germany are working on the development of a special surface coating that keeps the stent in place.

When coronary blood vessels are constricted, cardiologists try to prevent a heart attack by widening them with stent implants that stabilise the veins and arteries, improve the flow of blood and prevent vascular obliteration. These stents can be used to treat pathological constriction of the windpipe. This kind of respiratory stenosis, which may be caused by tumours, chronic infections or congenital deformities, can be life-threatening. In such cases, the metal or plastic stents are designed to enlarge the trachea and prevent it from closing up altogether. However, the stent implant can slip out of position, closing off the windpipe altogether. Bacteria can also colonise the stents and trigger pneumonia. The reason for this is that the stents have no barrier-forming cells of the kind usually present in the respiratory system, whose task is to fend off bacteria and inhaled substances such as particulate.

Dr Martina Hampel, a scientist at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart, working with Professor Thorsten Walles, head of the department of thoracic surgery at the University Hospital of Würzburg and a visiting scientist at the IGB, participated  in the “REGiNA” project, the goal of which was to develop surface coatings that enable the stents to be incorporated in the surrounding tissue, thereby reducing the risk that they will move. REGiNA, a German acronym for Regenerative Medicine in the Neckar-Alb and Stuttgart Region, is funded by the German Federal Ministry of Education and Research (BMBF).

The scientists used stents lined with a polyurethane (PU) film, which were produced by Aachen-based Leufen Medical. In the subsequent tests, a wide variety of different coatings were applied to the PU film. In addition to synthetic polymers composed of organic acids, the researchers also tried out biological proteins such as fibronectin and type-I collagen. The coating was modified again using plasma technology, with vacuum-ionised gas being used to treat the surface. The experts used an untreated PU film for control purposes.

In order to find out which of the surface coatings was the most suitable, the researchers brought both lab-cultivated cell lines and human primary tracheal epithelial cells into contact with the films in cell culture vessels. The primary goal was for the primary respiratory cells from human tissue to attach themselves to the film. The researchers achieved their best results with the protein-coated film, on which the primary tracheal epithelial cells grew particularly well and multiplied. The team found that whilst respiratory cells proved to be more vital on bioactive films rather than on ones treated with plasma, polymer-coated film turned out to be “completely useless.”

The laboratory tests have since been completed, and animal tests are currently being prepared. If the lab results are confirmed in these tests, the next step will be to conduct clinical trials of the modified stents at the Schillerhöhe specialist lung clinic, a part of the Robert Bosch Hospital. The hope is that, within a few years, well-tolerated, cell-compatible surface coatings will be available for use in other biomedical prostheses, such as pacemaker leads, tooth implants and replacement joints.

Article Source: Cardiovascular Device Business

 




Espicom Business Intelligence

Latest report on Cardiovascular Device Companies

The Medical Technology Blog

New report published – Cardiovascular Device Companies: Surveying the Global Competitive Landscape

This week sees the release of a new report published by Espicom Business Intelligence entitled Cardiovascular Device Companies – Surveying the global competitive landscape.

Whilst it doesn’t take a genius to conclude that the cardiovascular device market is a fast changing industry, it’s often very difficult to view these changes close up. It’s been seven years since we produced our first report focused on the Cardiovascular sector, and those changes keep on coming as we head towards 2013.

For a period of time, much of the focus was all about drug-eluting stents, and for a while at least the technology looked like fulfilling its potential. In truth, the technology has faced a perfect storm of bad news that has dogged its progress. First up, there was the pricing and cost-effective issue, then came subsequently panned EU data that suggested restenosis rates were just too high and last of all, this seemingly relentless worldwide recession came along and neatly priced potential customers out of the technology.

Last year came the unexpected news that continued declines in DES sales had persuaded Cordis to quit the industry. But it’s not all doom and gloom because the removal of a major competitor might actually reduce overcapacity in the sector. Technological improvements have come in the form of biodegradeable DESs and lessons have been learned in terms of product development and research.

The issue of reabsorbable DESs also features in the report overview section – a 14-page look at the regulatory climate in the US and in Europe. As Abbott stands poised to get marketing approval for its Absorb bioabsorbable vascular scaffold more than 18 months after European authorities gave its approval, we examine whether the FDA needs to more to bridge this gap or whether the EU system is just too quick for its own good.

It’s not just DESs that are the focus of attention. Edwards Lifesciences is also enjoying the fruits of long-term research and working its way through the somewhat unpredictable FDA pathway to get commercial release of its Sapien transcatheter heart valve. And boy, is the cash rolling in for the company in the US, where it dominates the market! Last year, transcatheter heart valve sales for Edwards jumped by over 60 per cent and now total US$334 million. That technology seems to have taken an age to get to the US market and some say the delay has effectively cost thousands of lives that could have been saved. Strong criticism indeed!

A detailed review of over 60 companies

This year the report has 60 companies that span the full breadth of the cardiovascular device field, ranging from cardiac rhythm management to interventional cardiology. Interestingly, after a long period of research and product fine tuning, the market for cardiac assist devices, such as ventricular assist devices, implantable heart replacement devices and other similar devices look to be approaching the first stage in the commercial endgame. The tell-tale sign is further consolidation within the industry and the focus on building a body of data to support the longevity of respective technologies.

One cannot also forget the rising profile of the renal denervation system, which represents a non-drug treatment option for hypertension. A reduction in systolic blood pressure, a function that underpins the technology, has cut incidents of stroke, heart disease and mortality. Most of the big players – including St Jude Medical and Medtronic – are working on significant trials of the devices, but it is also being driven by much smaller companies that want a slice of the action.

So there’s a lot to read – and a lot to take in and consider – about this year in our newly updated, and ever changing Cardiovascular Device Companies – Surveying the global competitive landscape report.

For more information regarding this report visit www.espicom.com/cdev

 




Espicom Business Intelligence

i-Optics starts major sales push

The Medical Technology Blog

i-Optics starts major sales push for its corneal topographer system

Welcome back to the Medical Technology Blog, we have a great post today provided by our medical newsletters team-leader, Lawrence Miller, Lawrence is the editor for Medical Industry Week, please read on…

Investors certainly seem happy enough with the progress of the Netherlands-based ophthalmic diagnosis company, I-Optics, which this week has unveiled a corneal topographer system, called Cassini, that is designed to detect higher order aberrations with far better precision and accuracy than with ring topographers. The release took place at the the annual meeting of the British Contact Lens Association and follows the completion of a series D financing round that resulted in the company’s coffers increasing by EUR .7 million.

Specifically aimed at expanding the market for multifocal, toric, aspheric and ortho-k contact lenses, the system aims to meet the challenges of opticians and optometrists in ensuring accuracy in fitting such devices in patients with premium contact lenses. The unveiling also follows on from another tipped for 2012 growth development, namely the EasyScan non-mydriatic retinal imaging system, which was released in late 2011.

Cassini is based upon colour LED topography (CLT), which has been developed with the Amsterdam VU Medical Centre and replaces the rings used in Placido topographers with 672 colour-coded LEDs set in a pattern, thereby offering superior precision and accuracy, also for dry eyes and irregular corneas. The technology can measure high and low order aberrations precisely and in any direction, in contrast to Placido topographers that are limited to accurate measurements in a radial direction. Further refinements of the technology could potentially include early keratoconus detection and progression monitoring, cataract and refractive surgery and LASIK surgery.

Keratoconus affects approximately three million patients worldwide, and early diagnosis is key to ensuring the best possible treatment. The CLT could potentially detect the condition and other corneal irregularities due to to its ability to measure small aberrations with submicron accuracy and precision. The indication is currently being tested in a patient study being carried out at an undisclosed eye healthcare centre.

Longer term, it could also be possible to measure the power and shape of intraocular lenses (IOL) more precisely by combining Cassini’s CLT technology with further technology that measures the axial length, anterior chamber size and other parameters for IOL fitting. I-Flow says the current devices generate a post-op error of 0.5D, whilst using Cassini could reduce this to 0.2D and result in a smaller number of patients requiring glasses after the procedure.

Article Source: Medical Industry Week




Espicom Business Intelligence
 Page 1 of 12  1  2  3  4  5 » ...  Last » 

Web Hosting by HostGator